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Abstract
Background: Postpartum haemorrhage remains an important cause of maternal death despite treatment
with conventional therapy. Uncontrolled studies and one randomised comparison with conventional
oxytocics have reported dramatic effects with high-dose misoprostol, usually given rectally, for treatment
of postpartum haemorrhage, but this has not been evaluated in a placebo-controlled trial.
Methods:  The study was conducted at East London Hospital Complex, Tembisa and Chris Hani
Baragwanath Hospitals, South Africa. Routine active management of the third stage of labour was
practised. Women with more than usual postpartum bleeding thought to be related to inadequate uterine
contraction were invited to participate, and to sign informed consent. All routine treatment was given
from a special 'Postpartum Haemorrhage Trolley'. In addition, participants who consented were enrolled
by drawing the next in a series of randomised treatment packs containing either misoprostol 5 × 200 µg
or similar placebo, which were given 1 orally, 2 sublingually and 2 rectally.
Results: With misoprostol there was a trend to reduced blood loss ≥500 ml in 1 hour after enrolment
measured in a flat plastic 'fracture bedpan', the primary outcome (6/117 vs 11/120, relative risk 0.56; 95%
confidence interval 0.21 to 1.46). There was no difference in mean blood loss or haemoglobin level on day
1 after birth < 6 g/dl or blood transfusion. Side-effects were increased, namely shivering (63/116 vs 30/118;
2.14, 1.50 to 3.04) and pyrexia > 38.5°C (11/114 vs 2/118; 5.69, 1.29 to 25). In the misoprostol group 3
women underwent hysterectomy of whom 1 died, and there were 2 further maternal deaths.
Conclusions: Because of a lower than expected incidence of the primary outcome in the placebo group,
the study was underpowered. We could not confirm the dramatic effect of misoprostol reported in
several unblinded studies, but the results do not exclude a clinically important effect. Larger studies are
needed to assess substantive outcomes and risks before misoprostol enters routine use.
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Background
Excessive bleeding from the genital tract after birth, or
postpartum haemorrhage (PPH) is the major cause of
maternal deaths in many low-income countries. The glo-
bal estimate is 125,000 deaths per year [1]. In South
Africa, 240 of 2,445 maternal deaths reported between
1999 and 2001 were due to postpartum haemorrhage, the
third most common cause [2]. In a community-based
study in Senegal, estimates of maternal mortality ratio in
three regions ranged from 436 to 852 per 100,000 live
births. Two-thirds were due to direct obstetric causes, the
commonest being haemorrhage [3]. In the United King-
dom, the risk of maternal death from haemorrhage is
about 1 in 100 000 births [4]. The potential to save moth-
ers' lives with medical interventions for haemorrhage is
thus considerable.
There is good evidence that a policy of active management
of the third stage of labour [5], and one component of
active management, the routine administration of uterot-
onics (drugs to contract the uerus) such as oxytocin [6] or
oxytocin and ergometrine [7], are effective in reducing the
risk of postpartum haemorrhage.
When postpartum haemorrhage occurs, a number of med-
ical and surgical interventions are used to control the
bleeding [8]. A crucial aspect of both prevention and treat-
ment of postpartum haemorrhage is uterotonic therapy.
The most commonly used agents are injectable oxytocin
and/or ergometrine.
Misoprostol is a methyl ester (a synthetic analogue) of
natural prostaglandin E1. It is marketed and registered for
use in the prevention and treatment of peptic ulcer disease
caused by prostanglandin synthetase inhibitors. Adminis-
tered orally or sublingually, peak plasma concentrations
of misoprostolic acid are achieved in less than 30 minutes
[9]. It is a thermostable drug [9] and is relatively
inexpensive.
Administered orally or vaginally, it is an effective agent for
the induction of abortion [10] and of labour [11].
Misoprostol for routine prevention of postpartum 
haemorrhage
Oral and rectal misoprostol have been used for routine
management of the third stage of labour (after the birth).
Several small trials have given conflicting results. The
main side-effects have been shivering and pyrexia, which
are dose-dependent [12]. In the large WHO Collaborative
Trial of Misoprostol in the Management of the Third Stage
of Labour [13] and a systematic review of the topic [14],
blood loss >1,000 ml and use of additional oxytocics (the
primary outcomes in the WHO trial) were more frequent
with misoprostol than with injectable oxytocics, indicat-
ing that injectable oxytocics should remain the drug of
choice for routine prophylaxis. On the other hand, blood
transfusion was used less frequently in the misoprostol
group. This may have been a chance occurrence (it was
not a primary outcome for the trial). Secondly, there
could be a synergistic pharmacological effect between
misoprostol and conventional uterotonics, which were
given to most women with increased blood loss. Many
women in the misoprostol group thus received misopros-
tol as well as conventional uterotonics, whereas those in
the oxytocin group received only conventional oxytocics.
Thirdly, we have suggested in the report of a pharmacoki-
netic study linked to the WHO trial that the longer time to
peak levels of misoprostol (20–30 minutes) than syntoci-
non (3 minutes) may account for more early blood loss
with misoprostol [15]. This does not exclude the possibil-
ity that misoprostol may have an effect on more persistent
bleeding. Physiological studies have also shown a more
rapid onset of uterine contractions following syn-
tometrine than misoprostol after delivery [16].
Misoprostol has been widely recommended for the pre-
vention of postpartum haemorrhage when other methods
are not available [17].
Misoprostol for treatment of postpartum haemorrhage
Apart from the prophylactic use of misoprostol in the
third stage of labour, the therapeutic use of misoprostol
for the treatment of postpartum haemorrhage has been
promoted on the basis of unblinded studies. In a system-
atic review [18] we located 6 uncontrolled reports (41
women) [19-24] and one small, unblinded randomised
trial [25]. This method has entered clinical use, particu-
larly in developing countries, without systematic research
to document the optimal route and dosage, effectiveness
or risks of this treatment. The urgent need for randomised
trials of this new intervention has been emphasised [26].
If effective it could have a major impact on maternal mor-
tality, particulary in under-resourced countries. If not, its
use should be discouraged because of the dangers of side-
effects, and the risks associated with widespread introduc-
tion of misoprostol into health systems in which it might
be used for labour induction in inappropriate doses, with
the risk of fetal compromise and uterine rupture [27,28].
Route and dosage of misoprostol
The most common regimens reported for the treatment of
postpartum haemorrhage are 800 [23] or 1,000 µg [19,21]
rectally. We reviewed the literature on the pharmacokinet-
ics of misoprostol administered by various routes [18].
The oral route has the most rapid uptake, but the shortest
duration. The rectal route has slow uptake but prolonged
duration. The buccal or sublingual route has rapid uptake,
prolonged duration and greatest total bioavailability. In
order to improve the rapidity of onset of action and theBMC Pregnancy and Childbirth 2004, 4:16 http://www.biomedcentral.com/1471-2393/4/16
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overall bioavailability, we modified the reported practice
of using 1,000 µg rectally, by administering 200 µg orally,
400 µg sublingually and 400 µg rectally.
Objective
The objective of this study was to determine the side-
effects and effectiveness of high-dose misoprostol for the
treatment of postpartum haemorrhage by means of a dou-
ble-blind, placebo-controlled, randomised clinical trial.
The hypothesis was that measured blood loss of 500 ml or
more in the hour after enrolment would be significantly
less frequent in the misoprostol than in the placebo
group.
Methods
The study was conducted at the East London Hospital
Complex (Frere Maternity and Cecilia Makiwane Hospi-
tals, Eastern Cape) and Tembisa and Chris Hani Baragwa-
nath Hospitals, Gauteng, South Africa, between Jan 2002
and Dec 2003. All are busy referral hospitals.
Treatment packs were prepared independently, ordered in
computer-generated random sequence and numbered
consecutively. The packs contained either misoprostol 5 ×
200 µg or inactive placebo.
The treatment sequence was kept sealed, and the code
broken only after complete entry and checking of all trial
data.
A confidential interim analysis, blind to which group was
which, was performed by AMG after the first 100 enrol-
ments. Evidence of clear benefit or harm for either group
would have prompted stopping the trial, which was not
the case.
Women in labour were given basic information about the
trial in the form of notices in the labour rooms (Table 2
[see additional file 1]). Management of labour 3rd stage
was routine active management with oxytocin 10 units or
syntometrine one ampoule soon after the birth. Women
aged 18 or more with bleeding judged by the clinician to
be more than expected at least 10 minutes after delivery,
and thought to be due to uterine atony and requiring
additional uterotonic therapy, were given all the routine
treatment for PPH (intravenous infusion, uterotonics, etc)
from a special 'PPH Trolley' kept in the labour ward. The
uterotonics used were oxytocin by intravenous infusion,
and/or oxytocin/ergometrine, at the discretion of the
attending clinician. Prostaglandin preparations such as
sulprostone were not routinely available in the labour
wards, and were not part of routine management of post-
partum haemorrhage in the participating units.
Once all emergency treatment was instituted, and if the
women were in a position to give fully informed consent,
they were given detailed information about the trial and
asked whether they wished to participate. Information
about the trial was given verbally and in writing in English
or Xhosa (Table 3 [see additional file 2]). Those who gave
written consent were enrolled in the trial. Baseline data
were documented. The next treatment pack containing
either misoprostol 5 × 200 µg or inactive placebo was
drawn and the number recorded. In addition to routine
management, misoprostol or placebo (an inactive base)
were given, 1 orally, 2 buccally/sublingually and 2 rec-
tally, and the time recorded.
A low-profile plastic 'fracture bedpan' was placed under
the woman's buttocks. In previous studies we have shown
this to be an efficient method of collecting ongoing blood
loss with very little spillage [29]. Any small swabs soaked
with blood were dropped into the bedpan. After 1 hour,
the blood collected in the bedpan was measured in a grad-
uated measuring jug, the temperature was measured sub-
lingually with a mercury thermometer, and any shivering
was subjectively recorded as 'mild' (not causing any dis-
tress), 'moderate' or 'severe'.
All other management was by hospital staff according to
the hospital routine for the management of postpartum
haemorrhage.
After 24 hours, blood was collected for haemoglobin esti-
mation and the hospital records checked for use of addi-
tional uterotonics and any other complications such as
blood transfusion.
The primary outcome measures were specified prior to
commencing the study: (1) measured blood loss ≥500 ml
in 1 hour after enrolment; (2) mean measured blood loss
in 1 hour after enrolment; (3) haemoglobin level day 1
after birth <6 g/dl or blood transfusion; (4) Side-effects
(pyrexia 38.5°C or more, moderate or severe shivering 1
hour after enrolment).
Secondary outcome measures were: (1) blood loss ≥1,000
ml in 1 hour after enrolment; (2) blood transfusion; (3)
haemoglobin level 1 day after birth <8 g/dl or blood trans-
fusion; (4) additional uterotonic given after enrolment;
(5) manual removal of the placenta; (6) evacuation of
retained products of conception; (7) hysterectomy; (8)
maternal death.
Sample size calculation
In the WHO misoprostol trial control group (routine syn-
tocinon), significant postpartum haemorrhage (blood
loss >1000 ml) occurred in 2.8% of women. Of these 25%
lost >1,500 ml. To reduce blood loss >500 ml afterBMC Pregnancy and Childbirth 2004, 4:16 http://www.biomedcentral.com/1471-2393/4/16
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enrolment from 25% to 10%, would require 112 per
group (α = 95%, β = 80%).
Data were collected on a data form, entered onto an excel
spreadsheet, checked for accuracy, then analysed using
Epi-info 2002 (United States Department of Health and
Human Services, Centres for Diseases Control and Preven-
tion, Epidemiology Program Office) and Review Manager
(RevMan) [Computer program] version 4.2 for Windows.
Oxford, England: The Cochrane Collaboration, 2003.
Results were expressed as relative risks or mean difference
with 95% confidence intervals. Analysis was by intention
to treat.
Ethical considerations
All women enrolled in the trial received all the conven-
tional management available for postpartum haemor-
rhage, in addition to the trial medication (misoprostol or
placebo). Rapid conventional therapy was facilitated by
the ready availability of the 'PPH trolley' with all the nec-
essary materials. This trolley was also available for women
not enrolled in the trial. Participation was limited to
women who were in a position to give fully informed con-
sent. Ethical approval was given by the Committee for
Research on Human Subjects, University of the Witwa-
tersrand, and the Ethics Committee, East London Hospi-
tal Complex. The trial complied with the Helsinki
Declaration for research on human subjects.
Results
Altogether 244 women were enrolled in the trial. The pack
numbers for 6 women were incompletely filled in on the
data sheets. The group allocation of these women was
therefore unknown, and they could not be included in the
analysis. Of these 6 women, the highest measured blood
loss after enrolment was 220 ml; none had pyrexia
>37.5°C, one had moderate shivering, one had a blood
transfusion and none had day 1 haemoglobin level below
8 g/dl or other complications. There was no reason to
expect that these exclusions occurred in any selective way
which would introduce bias into the final samples, nor
could their results have materially altered the conclusions
of the study. All the remaining 238 women were included
in the analyses.
The baseline characteristics are shown in table 1. As would
be expected in a randomised trial, the groups were well
matched. Parity was not recorded at all hospitals, but was
similar between groups where recorded (misoprostol
mean 1.61, SD 1.14; placebo 1.75, SD 1.26).
The outcomes are shown in table 1. In the placebo group,
the primary outcome (measured blood loss within 1 hour
after enrolment of 500 ml or more) was less frequent
(9.2%) than the 25% prediction on which the sample size
calculation was based. This may have been because the
criteria for enrolment were loosely defined as 'more than
expected blood loss', resulting in the enrolment of women
with less severe blood loss than anticipated. The fact that
enrolment was limited to women who were able to
received detailed information about the study, may have
caused selection of less severe cases. Although the inten-
tion was to enrol women who had not responded to con-
ventional therapy, the time taken for counselling of the
women and obtaining informed consent may have
resulted in some women responding to the primary treat-
ment, and therefore the low rate of ongoing blood loss in
the placebo group. The study was thus underpowered to
detect a statistically significant reduction in the primary
outcome. With misoprostol there was a trend to reduced
blood loss ≥500 ml in 1 hour after enrolment (6/117 vs
11/120, relative risk 0.56; 95% confidence interval 0.21 to
1.46).
Other proxy estimations of blood loss showed no signifi-
cant differences between the groups. The well-known
side-effects of misoprostol, pyrexia and shivering, were
significantly more frequent in the misoprostol than the
placebo group.
Serious morbidity or mortality occurred in 5 women, all
from the misoprostol group. Two women who continued
to bleed despite conservative therapy underwent abdomi-
nal hysterectomy and recovered well. There were 3 mater-
nal deaths:
Case 1
A 22-year old woman with one previous pregnancy devel-
oped postpartum haemorrhage after vaginal delivery,
managed with a 40-unit oxytocin infusion. She was
enrolled and received the trial medication 85 minutes
after delivery. Thereafter she received a second 40-unit
oxytocin drip, oxytocin/ergometrine (5 units/0.5 mg) and
intravenous cyclokapron. In the hour after randomisa-
tion, measured blood loss was 125 ml. Subsequently
bleeding continued and a sub-total hysterectomy was per-
formed. Coagulopathy developed, bleeding continued
through an abdominal drain, and she died 2 days after
delivery despite re-laparotomy and multiple blood prod-
uct transfusions.
Case 2
A 32-year-old woman, para 2, gravida 4, delivered nor-
mally after labour was induced with misoprostol, 25 µg
vaginally and 4 doses of 50 µg orally. Before enrolment
she received oxytocin10 units, ergometrine 0.5 mg and a
20-unit oxytocin infusion. She was enrolled and received
the trial medication 140 minutes after delivery. After
enrolment she received a further 40-unit oxytocin infu-
sion. Measured blood loss in the hour after enrolment wasBMC Pregnancy and Childbirth 2004, 4:16 http://www.biomedcentral.com/1471-2393/4/16
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380 ml. Bleeding continued and a blood transfusion was
commenced. Six and a half hours after delivery she suf-
fered a cardiac arrest and was resuscitated. Examination in
theatre found the uterus to be empty and intact. The main
source of bleeding appeared to be a torn cervix, which was
sutured. At 7.5 hours after delivery she suffered a second
cardiac arrest and could not be resuscitated. The estimated
total blood loss was 3,000 ml.
Case 3
A woman with one previous delivery by caesarean section,
developed postpartum haemorrhage of about 500 ml
after a vaginal delivery. She was enrolled 85 minutes after
delivery. Measured blood loss over the next hour was 425
ml, after which she developed hypotension and cardiores-
piratory arrest. As no post-mortem examination was per-
formed, the possibility of internal bleeding from a
dehisced caesarean section scar could neither be con-
firmed nor excluded.
Unresponsive uterine atony was therefore not confirmed
as the main cause of any of the deaths.
Discussion
Pyrexia and shivering were common side-effects of miso-
prostol, as found in previous studies. Three women, all in
the misoprostol group, had severe pyrexia >40°C. Previ-
ous studies of high-dose misoprostol for the treatment of
postpartum haemorrhage have mostly used the rectal
route, and none has had sufficient numbers to be likely to
detect rare adverse outcomes such as severe pyrexia. These
side-effects may be related to the rapid absorption of mis-
oprostol given orally, and the rapid absorption and high
bioavailability when given sublingually. Because of these
serious side-effects, we would recommend that for future
trials the dose be reduced.
Several previous unblinded studies have reported dra-
matic effects of misoprostol when used to treat postpar-
tum haemorrhage. In 6 observational studies [19-24], 41
women with postpartum haemorrhage were treated with
misoprostol 1,000 µg rectally (32 women), 200 µg rectally
(5 women), 200 µg orally 2-hourly (2 women) or 800 µg
intrauterine (2 women). In all but 2 of the women (who
received 1,000 µg rectally), a prompt response to the treat-
ment was reported. In a single blind randomised trial [25]
subjective prompt cessation of bleeding was reported in
30/32 women who received misoprostol 800 µg rectally
Table 1: Comparison of outcomes between women who received misoprostol or placebo, expressed as proportions (percent) or mean 
values [standard deviation]. Differences are expressed as relative risks or mean differences, with 95% confidence intervals.
Misoprostol (117) Placebo (121)
Baseline characteristics n n
Age (years) 116 27.1 [6.0] 119 26.2 [6.2]
Ergometrine before enrolment 106 36 (34%) 104 34 (33%)
Oxytocin ≥20 U before enrolment 116 82 (71%) 117 78 (67%)
Primary outcomes: RR/ MD 95% Conf. 
interval
Blood loss ≥500 ml* 117 6 (5.1%) 120 11 (9.2%) 0.56 0.21 to 1.46
Mean blood loss* [SD] (ml) 117 168 [163] 120 176 [173] -8 -51 to 35
24 hour Haemoglobin <6 g/dL or blood transfusion 110 20 (18.2%) 116 17 (14.7%) 1.24 0.69 to 2.24
Pyrexia at 1 hour ≥38, 5°C 114 11 (9.6%) 118 2 (1.7%) 5.69 1.29 to 25
Shivering at 1 hour ≥ moderate 116 63 (54%) 118 30 (25%) 2.14 1.50 to 3.04
Secondary outcomes:
Blood loss ≥ 1,000 ml* 117 1 (0.85%) 120 0 (0%)
Blood transfusion 115 19 (17%) 119 15 (13%) 1.31 0.70 to 2.45
24 hour haemoglobin <8 g/dL or blood transfusion 110 43 (39%) 116 37 (32%) 1.23 0.86 to 1.75
Additional uterotonic after enrolment 111 63 (57%) 112 63 (56%) 1.01 0.80 to 1.27
Manual removal of the placenta 117 1 (0.85%) 121 4 (3.3%) 0.26 0.03 to 2.28
Evacuation of retained products of conception 117 2 (1.7%) 121 0 (0%)
Hysterectomy** 117 3 (2.6%) 121 0 (0%)
Maternal death** 117 3 (2.6%) 121 0 (0%)
RR = relative risk; MD = mean difference; Conf = confidence; SD = standard deviation *Measured, within 1 hour after enrolment ** One woman 
died after hysterectomy and is counted in both outcomesBMC Pregnancy and Childbirth 2004, 4:16 http://www.biomedcentral.com/1471-2393/4/16
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compared with only 21/32 who received oxytocin 5 units
plus ergometrine 0.5 mg intramuscularly.
Conclusions
In our double blind trial we have been unable to confirm
the dramatic effects of misoprostol reported previously in
unblinded studies. Our results, however, are consistent
with anything from a large beneficial effect to a smaller
adverse effect (relative risk of additional blood loss of 500
ml or more anywhere between a reduction of 79% and an
increase of 46% with misoprostol). It is important that
this possible benefivial effect be assessed by sufficiently
powered randomised trials before the treatment enters
routine clinical use.
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